Android app Apple app link

Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA

By Yahoo! Finance   |   1 month ago
Merck & Co (MRK) RSV Antibody for Infants Approved by US FDA

Merck & Co., Inc. (NYSE:MRK) has developed a preventative antibody shot named Enflonsia for infants against RSV. This shot is expected to be available for the 2025-2026 RSV season, pending CDC approval.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.